- Home
- KEQU
as of 03-18-2026 3:34pm EST
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
| Founded: | 1906 | Country: | United States |
| Employees: | N/A | City: | STATESVILLE |
| Market Cap: | 106.6M | IPO Year: | 1995 |
| Target Price: | N/A | AVG Volume (30 days): | 6.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | 2.09 | EPS Growth: | -39.97 |
| 52 Week Low/High: | $30.33 - $60.89 | Next Earning Date: | 03-11-2026 |
| Revenue: | $138,558,000 | Revenue Growth: | 7.72% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | 16.44 | Index: | N/A |
| Free Cash Flow: | 12.6M | FCF Growth: | +389.59% |
Stock Insider Trading Activity of Kewaunee Scientific Corporation (KEQU)
President, CEO
Avg Cost/Share
$37.50
Shares
2,177
Total Value
$81,637.50
Owned After
33,000
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$37.57
Shares
2,000
Total Value
$75,140.00
Owned After
9,564
SEC Form 4
President, CEO
Avg Cost/Share
$37.66
Shares
629
Total Value
$23,688.14
Owned After
33,000
SEC Form 4
President, CEO
Avg Cost/Share
$38.00
Shares
29
Total Value
$1,102.00
Owned After
33,000
SEC Form 4
President, CEO
Avg Cost/Share
$38.01
Shares
884
Total Value
$33,600.84
Owned After
33,000
SEC Form 4
President, CEO
Avg Cost/Share
$39.00
Shares
1,000
Total Value
$39,000.00
Owned After
33,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| HULL THOMAS DAVID III | KEQU | President, CEO | Jan 7, 2026 | Sell | $37.50 | 2,177 | $81,637.50 | 33,000 | |
| Gardner Donald T. III | KEQU | Chief Financial Officer | Jan 6, 2026 | Sell | $37.57 | 2,000 | $75,140.00 | 9,564 | |
| HULL THOMAS DAVID III | KEQU | President, CEO | Dec 31, 2025 | Sell | $37.66 | 629 | $23,688.14 | 33,000 | |
| HULL THOMAS DAVID III | KEQU | President, CEO | Dec 30, 2025 | Sell | $38.00 | 29 | $1,102.00 | 33,000 | |
| HULL THOMAS DAVID III | KEQU | President, CEO | Dec 29, 2025 | Sell | $38.01 | 884 | $33,600.84 | 33,000 | |
| HULL THOMAS DAVID III | KEQU | President, CEO | Dec 22, 2025 | Sell | $39.00 | 1,000 | $39,000.00 | 33,000 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 11, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLMar 11, 2026 · 100% conf.
1D
-8.19%
$37.62
Act: -1.06%
5D
-11.10%
$36.43
20D
-13.12%
$35.61
kequ-20260311KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292026-03-112026-03-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2026
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On March 11, 2026, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated March 11, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KEWAUNEE SCIENTIFIC CORPORATION
(Registrant)
Date: March 11, 2026 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K SELL Dec 10, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLDec 10, 2025 · 100% conf.
1D
-8.96%
$36.42
Act: -4.35%
5D
-12.76%
$34.90
Act: -2.80%
20D
-14.49%
$34.20
Act: -6.25%
kequ-20251210KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292025-12-102025-12-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2025
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On December 10, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the second quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated December 10, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KEWAUNEE SCIENTIFIC CORPORATION
(Registrant)
Date: December 10, 2025 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Sep 10, 2025
Q2 2025 Earnings
8-KSep 10, 2025
kequ-20250910KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292025-09-102025-09-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2025
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On September 10, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated September 10, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KEWAUNEE SCIENTIFIC CORPORATION
(Registrant)
Date: September 10, 2025 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Compare KEQU vs Leading Stocks
See how KEQU stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KEQU Kewaunee Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.